Skip to Content


Active Substance: darbepoetin alfa
Common Name: darbepoetin alfa
ATC Code: B03XA02
Marketing Authorisation Holder: Dompé Biotec S.p.A.
Active Substance: darbepoetin alfa
Status: Withdrawn
Authorisation Date: 2001-06-08
Therapeutic Area: Anemia Kidney Failure, Chronic Cancer
Pharmacotherapeutic Group: Antianemic preparations

Therapeutic Indication

Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and paediatric patients.
Treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.

The marketing authorisation for Nespo has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.